title: Effect of haemodialysis after contrast medium administration in patients with renal insufficiency.
abstract: BACKGROUND
  The study was designed to investigate the influence of haemodialysis on the pharmacokinetics of the non-ionic contrast medium iopentol and the outcome of radiocontrast nephropathy in patients at risk undergoing angiography.
  
  
  METHODS
  We prospectively studied 30 patients with reduced renal function (mean serum creatinine concentration (+/- SEM), 2.4 +/- 0.16 mg/dl (212 +/- 14 mumol/l)). Patients were randomly assigned to receive either a haemodialysis procedure for 3 h, started as soon as possible (63 +/- 6 min) after administration of contrast medium, or a conservative treatment. Serum concentrations of iopentol and creatinine were followed for up to 14 days.
  
  
  RESULTS
  The extracorporal plasma clearance of contrast medium was 71 +/- 2.5 ml/min. The fraction of the dose eliminated was 32 +/- 3%. The rate of radiocontrast nephropathy (defined as serum creatinine increase of > or = 0.5 mg/dl (44 mumol/l) within 48 h) after administration of contrast medium was similar in both groups (53 and 40% in group 1 (haemodialysis) and group 2 (conservative treatment) respectively). The course of absolute changes in serum creatinine over the whole observation period was not different in both groups.
  
  
  CONCLUSIONS
  The data indicate that haemodialysis eliminates contrast medium effectively, but it may not influence the incidence or outcome of contrast induced nephropathy.
authors.affiliation: Department of Medicine, University of Freiburg, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Lehnert
authors.forename: E
authors.initials: E
authors.lastname: Keller
authors.forename: K
authors.initials: K
authors.lastname: Gondolf
authors.forename: T
authors.initials: T
authors.lastname: Schäffner
authors.forename: H
authors.initials: H
authors.lastname: Pavenstädt
authors.forename: P
authors.initials: P
authors.lastname: Schollmeyer
mesh_terms: D003287:Contrast Media / Q000493:pharmacokinetics*; D003404:Creatinine / Q000097:blood; D005260:Female; D006207:Half-Life; D006801:Humans; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000378:metabolism* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D006435:Renal Dialysis; D014283:Triiodobenzoic Acids / Q000493:pharmacokinetics*
chemical_list: D003287:Contrast Media; D014283:Triiodobenzoic Acids; C053571:iopentol; D003404:Creatinine